Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
5.94
+0.13 (2.24%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.76 - 6.02
52 week 1.76 - 7.63
Open 5.81
Vol / Avg. 621,592.00/1.11M
Mkt cap 457.25M
P/E     -
Div/yield     -
EPS -0.98
Shares 78.70M
Beta 1.75
Inst. own 55%
Nov 10, 2014
Q3 2014 Amicus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 1, 2014
Amicus Therapeutics Inc at Leerink Rare Disease Roundtable
Aug 20, 2014
Amicus Therapeutics Inc Phase III Fabry Monotherapy Study Results Conference Call - Webcast
Aug 7, 2014
Q2 2014 Amicus Therapeutics Inc Earnings Call
Aug 7, 2014
Q2 2014 Amicus Therapeutics, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -3076.63% -16427.82%
Operating margin -3003.37% -17680.72%
EBITD margin - -16521.76%
Return on average assets -50.89% -50.19%
Return on average equity -173.96% -103.74%
Employees 92 -
CDP Score - -

Address

1 Cedar Brook Drive
CRANBURY, NJ 08512
United States - Map
+1-609-6622000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amicus Therapeutics, Inc. (Amicus) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. It is focused on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein. Amicus is also conducting preclinical studies on the use of its pharmacological chaperone technology to treat Parkinson�s disease, with an initial focus on Parkinson�s disease patients who are also Gaucher disease carriers.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Bradley L. Campbell Chief Operating Officer
Age: 38
Bio & Compensation  - Reuters
Hung Do Ph.D. Senior Vice President - Discovery Biology
Age: 46
Bio & Compensation  - Reuters
Ken Valenzano Ph.D. Senior Vice President - Preclinical Research
Age: 46
Bio & Compensation  - Reuters
Enrique Dilone Ph.D. Vice President - Technical Operations
Age: 47
Bio & Compensation  - Reuters
Daphne E. Quimi Vice President - Finance, Controller
Age: 48
Bio & Compensation  - Reuters
Jeffrey P. Castelli Ph.D. Vice President - Program and Portfolio Management
Age: 42
Bio & Compensation  - Reuters
Jayne Gershkowitz Vice President - Patient Advocacy & Public Policy
Age: 57
Bio & Compensation  - Reuters
John R. Kirk Vice President - Regulatory Affairs
Age: 57
Bio & Compensation  - Reuters